Reviewing the safety of erlotinib in non-small cell lung cancer
Publication in refereed journal

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要Importance of the field: Erlotinib, a potent inhibitor of EGFR activity, is approved as a monotherapy for the treatment of advanced NSCLC and in combination with gemcitabine for advanced pancreatic cancer. The oral administration and manageable toxicity of erlotinib, along with its similar efficacy to chemotherapy, make it an important option as either maintenance therapy or in second-/third-line for patients with NSCLC who have previously received first-line chemotherapy. It is also an emerging option in other treatment settings in NSCLC.
著者Reck M, Mok T, Wolf J, Heigener D, Wu YL
期刊名稱Expert Opinion on Drug Safety
出版年份2011
月份1
日期1
卷號10
期次1
出版社Taylor & Francis: STM, Behavioural Science and Public Health Titles
頁次147 - 157
國際標準期刊號1474-0338
電子國際標準期刊號1744-764X
語言英式英語
關鍵詞EGFR; erlotinib; NSCLC; TKI
Web of Science 學科類別Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

上次更新時間 2020-25-11 於 00:07